Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy

Table 1

Patient and control demographics.

	Control	Cohort
Age	51 ± 8	54 ± 12
Stages (I–III)	30 (100%)	26 (87%)
NYHA II-III	—	16 (53%)
Cardiac risk factor
Coronary artery disease	—	—
Hypertension	5 (17%)	6 (20%)
Diabetes mellitus	1 (3%)	3 (10%)
Dyslipidemia	—	3 (10%)
Smoker	3 (10%)	1 (3%)
Chemotherapeutic regimen
AC-TH		13 (43%)
Epirubicin mg/m^2	—	^*302.4 ± 10
FEC + DH		9 (30%)
Doxorubicin mg/m^2	—	^*231.2 ± 18.7
TCH		3 (10%)
TH		5 (17%)
Radiation		23 (77%)
Mastectomy		21 (70%)
Previous cancer^†		6 (20%)
Ventricular systolic function by MUGA (%)
LVEF
Prechemo	—	62 ± 5
At time of cardiotoxicity		48 ± 4
RVEF
Prechemo		45 ± 4
At time of cardiotoxicity		43 ± 6

Mean cumulative dose, 4 were previously diagnosed with breast tumor and at the time of the study were being treated for recurrence, and 2 had previous history of Ewing’s Sarcoma and Hodgkin’s lymphoma. AC-TH: doxorubicin and cyclophosphamide followed by either paclitaxel or docetaxel and trastuzumab; FEC-DH: 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel and trastuzumab; TCH: docetaxel, carboplatin or cyclophosphamide, and trastuzumab; TH: trastuzumab and docetaxel or paclitaxel.